And when a ribosome reads from this mRNA to make the protein, it reads inosine as though it was guanine. Thus, A-to-I mRNA ...

A new trial suggests a combination vaccine may offer equal or better protection against both flu and covid-19 compared to ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1389.55 with a total volume of ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Our premium News+ ad-free experience – only $10 more every 4 weeks!

The anti-mRNA sentiment — coupled with the sweeping shake-up of science funding across the United States — has sparked fears ...

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

Of course, a lot of upside could potentially be left on the table if MRNA shares really soar, which is why looking at the trailing twelve month trading history for Moderna Inc, as well as studying ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine ...

Seven percent of 108 healthy volunteers reported urticaria; unresolved urticaria persisted at 12 months in four participants.